Cost minimization analysis of subcutaneous or intravenous administration of trastuzumab and pertuzumab in breast cancer patients
Abstract
Introduction: Pharmacoeconomic evaluation of drugs for HER2-positive breast cancer is important, due to the high cost of these medications. Efficacy and safety results of combined subcutaneous administration of trastuzumab and pertuzumab are not lower than those of intravenous administration.
Objective: Compare the costs of three options for the combined administration of trastuzumab and pertuzumab: 1) in separate vials, both intravenous drugs; 2) subcutaneous trastuzumab and intravenous pertuzumab; and 3) both drugs in a single vial, subcutaneous.
Methods: A cost minimization analysis was performed of a one-year period. Attention was paid to costs associated to the administration of anti-HER2 drugs in 18-dose schemes, including the cost of specific drugs, consumables, human resources and monitoring. Univariate sensitivity analysis was carried out, in which the price of anti-HER2 drugs was varied ±10-30%.
Results: Total cost of combined subcutaneous administration of trastuzumab and pertuzumab at fixed doses was 26% lower than the separate vials scheme for anti-Her2 intravenous administration and 6% lower than the hybrid regimen. The time saved per treatment session per patient by scheme 3 was 83.8% of scheme 1 and 68% of scheme 2. Sensitivity analysis found that the subcutaneous treatment scheme was less costly than the intravenous scheme even when product costs are increased 30%.
Conclusions: Combined administration of trastuzumab and pertuzumab at fixed subcutaneous doses is more cost-effective and offers more organizational benefits to oncological services than other schemes. It is also a safe and efficient alternative for the national health system in the treatment of patients with HER2-positive breast cancer.
Key words: breast cancer; phamacoeconomics; trastuzumab; pertuzumab.Downloads
References
1. Ministerio de Salud Pública. Anuario Estadístico de Cuba 2020. MINSAP, Dirección Nacional de Registros Médicos y Estadísticas de Salud: La Habana. 2021 [acceso 11/08/2021]. Disponible en: https://files.sld.cu/bvscuba/files/2021/08/Anuario-Estadistico-Espa%c3%b1ol-2020-Definitivo.pdf
2. Sung H, Ferlay J, Siegel RL, Laverssane M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN Estimate of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3):209-49. doi:10.3322/caac.21660.
3. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. doi:10.3322/caac.21492.
4. Godone RLN, Leitão GM, Araújo NB, Castelletti CHM, Lima-Filho JL, Martins DBG. Clinical and molecular aspects of breast cancer: Targets and therapies. Biomed Pharmacother. 2018;106:14-34. doi:10.1016/j.biopha.2018.06.066.
5. Schick J, Ritchie RP, Restini C. Breast cancer therapeutics and biomarkers: past, present, and future approaches. Breast Cancer (Auckl). 2021;15:1178223421995854. doi: 10.1177/1178223421995854.
6. Zubair M, Wang S, Ali N. Advanced approaches to breast cancer classification and diagnosis. Front Pharmacol. 2021;11:632079. doi:10.3389/fphar.2020.632079.
7. Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet 2017; 389: 1195-1205. doi:10.1016/S0140-6736(16)32616-2.
8. Larionov AA. Current therapies for human epidermal growth factor receptor 2-positive metastatic breast cancer patients. Front Oncol. 2018;8:89. doi: 10.3389/fonc.2018.00089.
9. Heo YA, Syed YY. Subcutaneous Trastuzumab: A review in HER2-positive breast cancer. Target Oncol. 2019;14(6):749-58. doi:10.1007/s11523-019-00684-y.
10. Harbeck N, Beckmann MW, Rody A, Schneeweiss A, Müller V, Fehm T, et al. HER2 dimerization inhibitor pertuzumab - mode of action and clinical data in breast cancer. Breast Care (Basel). 2013;8(1):49-55. doi:10.1159/000346837.
11. Ishii K, Morii N, Yamashiro H. Pertuzumab in the treatment of HER2-positive breast cancer: an evidence-based review of its safety, efficacy, and place in therapy. Core Evid. 2019;14:51-70. doi: 10.2147/CE.S217848.
12. Brandão M, Pondé NF, Poggio F, Kotecki N, Salis M, Lambertini M, et al. Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects. Expert Rev Anticancer Ther. 2018;18(7):629-49. doi: 10.1080/14737140.2018.1477596.
13. Jagosky M, Tan AR. Combination of pertuzumab and trastuzumab in the treatment of HER2-positive early breast cancer: a review of the emerging clinical data. Breast Cancer (Dove Med Press). 2021;13:393-407. doi:10.2147/BCTT.S176514.
14. Jackisch C, Stroyakovskiy D, Pivot X, Ahn JS, Melichar B, Chen SC, et al. Subcutaneous vs intravenous trastuzumab for patients with erbb2-positive early breast cancer: final analysis of the HannaH phase 3 randomized clinical trial. JAMA Oncol. 2019;5(5):e190339. doi: 10.1001/jamaoncol.2019.0339.
15. Tan AR, Im SA, Mattar A, Colomer R, Stroyakovskii D, Nowecki Z, et al. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study. Lancet Oncol. 2021;22(1):85-97. doi: 10.1016/S1470-2045(20)30536-2.
16. Ramón I, Soriano JL, Valenciano ML, Batista N, Lima M, Duvergel D, et al. Supervivencia de pacientes con cáncer mamario temprano Her-2 positivo tratadas con trastuzumab endovenoso en adyuvancia. Revista Cubana de Oncología. 2021[acceso 11/08/2021]; 19 (1):e_91. Disponible en: http://revoncologia.sld.cu/index.php/onc/article/view/91/50
17. Schnipper LE, Davidson NE, Wollins DS, Tyne C, Blayney DW, Blum D, et al. American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol. 2015;33(23):2563-77. doi: 10.1200/JCO.2015.61.6706.
18. Iskrov G, Dermendzhiev S, Miteva-Katrandzhieva T, Stefanov R. Health economic data in reimbursement of new medical technologies: importance of the socio-economic burden as a decision-making criterion. Front Pharmacol. 2016;7:252. doi: 10.3389/fphar.2016.00252.
19. Soto J. Fundamento e introducción a la evaluación económica de medicamentos y tecnologías sanitarias. En: Evaluación económica de medicamentos y tecnologías sanitarias. Madrid: Springer SBM, Spain, S.A.U; 2012.
20. Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, and CLEOPATRA study group. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(4):519-30. doi: 10.1016/S1470-2045(19)30863-0.
21. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25-32. doi: 10.1016/S1470-2045(11)70336-9.
22. von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, and APHINITY Steering Committee and Investigators. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017;377(2):122-31. doi: 10.1056/NEJMoa1703643.
23. Pivot X, Verma S, Fallowfield L, Müller V, Lichinitser M, Jenkins V, and PrefHer Study Group. Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study. Eur J Cancer. 2017;86:82-90. doi: 10.1016/j.ejca.2017.08.019.
24. Gligorov J, Ataseven B, Verrill M, De Laurentiis M, Jung KH, Azim HA, and SafeHer Study Group. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. Eur J Cancer. 2017;82:237-46. doi: 10.1016/j.ejca.2017.05.010.
25. Kuemmel S, Tondini CA, Abraham J, Nowecki Z, Itrych B, Hitre E, et al. Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study. Breast Cancer Res Treat. 2021;187(2):467-76. doi: 10.1007/s10549-021-06145-3.
26. Kirschbrown WP, Wynne C, Kågedal M, Wada R, Li H, Wang B, et al. Development of a subcutaneous fixed-dose combination of pertuzumab and trastuzumab: results from the Phase Ib dose-finding study. J Clin Pharmacol. 2019;59(5):702-16. doi: 10.1002/jcph.1362.
27. DuMond B, Patel V, Gross A, Fung A, Weber S. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive breast cancer: A multidisciplinary approach. J Oncol Pharm Pract. 2021;27(5):1214-21. doi: 10.1177/1078155221999712.
28. Lázaro-Cebas A, Cortijo.Cascajares S, Pablos-Bravo S, Del Puy Goyache-Goñi M, González-Monterrubio G, Pérez-Cárdenas MD, et al. Subcutaneous versus intravenous administration of trastuzumab: preference of HER2+ breast cancer patients and financial impact of its use. J BUON. 2017;22(2):334-9. PMID: 28534353.
29. Olsen J, Jensen KF, Olesen DS, Knoop A. Costs of subcutaneous and intravenous administration of trastuzumab for patients with HER2-positive breast cancer. J Comp Eff Res. 2018;7(5):411-9. doi: 10.2217/cer-2017-0048.
30. Farolfi A, Silimbani P, Gallegati D, Petracci E, Schirone A, Altini M, et al. Resource utilization and cost saving analysis of subcutaneous versus intravenous trastuzumab in early breast cancer patients. Oncotarget 2017;8:81343-9. doi:10.18632/oncotarget.18527.
31. De Cock E, Pivot X, Hauser N, Verma S, Kritikou P, Millar D, et al. A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer. Cancer Med. 2016;5(3):389-97. doi: 10.1002/cam4.573.
32. Papadmitriou K, Trinh XB, Altintas S, Van Dam PA, Huizing MT, Tjalma WA. The socio-economical impact of intravenous (IV) versus subcutaneous (SC) administration of trastuzumab: future prospectives. Facts Views Vis Obgyn. 2015;7(3):176-80. PMID: 26977267.
33. Lieutenant V, Toulza É, Pommier M, Lortal-Canguilhem B. Is Herceptin(®) (trastuzumab) by subcutaneous a mini revolution? Pharmaco-economic study. Bull Cancer. 2015;102(3):270-6. doi: 10.1016/j.bulcan.2015.01.007.
34. O'Brien GL, O'Mahony C, Cooke K, Kinneally A, Sinnott SJ, Walshe V, et al. Cost minimization analysis of intravenous or subcutaneous trastuzumab treatment in patients with HER2-positive breast cancer in Ireland. Clin Breast Cancer. 2019;19(3):e440-e451. doi: 10.1016/j.clbc.2019.01.011.
35. Ponzetti C, Canciani M, Farina M, Era S, Walzer S. Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin's lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey. Clinicoecon Outcomes Res. 2016;8:227-33. doi: 10.2147/CEOR.S97319.
36. Lakdawalla DN, Doshi JA, Garrison LP Jr, Phelps CE, Basu A, Danzon PM. Defining elements of value in health care-a health economics approach: An ISPOR special task force report [3]. Value Health. 2018;21(2):131-9. doi:10.1016/j.jval.2017.12.007.
37. Hughes D, Cowell W, Koncz T, Cramer J; International Society for Pharmacoeconomics & Outcomes Research Economics of Medication Compliance Working Group. Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations. Value Health. 2007;10(6):498-509. doi:10.1111/j.1524-4733.2007.00205.x.
38. Manevy F, Filkauskas G, Levy P, Fredriksson J, Sussell J. Potential non-drug cost differences associated with the use of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in the treatment of HER2-positive early breast cancer patients in Western Europe and the United States. J Clin Oncol. 2021;39:(suppl 15) 544. doi:10.1200/JCO.2021.39.15_suppl.544
Downloads
Published
How to Cite
Issue
Section
License
Esta revista provee acceso libre e inmediato a su contenido bajo el principio de que hacer disponible gratuitamente la investigación al público apoya a un mayor intercambio de conocimiento global.
Esto significa que se permite su copia y distribución por cualquier medio siempre que mantenga el reconocimiento de sus autores, no haga uso comercial de las obras y no realice ninguna modificación de ellas.
El envío de manuscritos, el procesamiento y la publicación no ofrece ningún coste a los autores, es totalmente gratis.
